Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes
Pribyl M, Hubackova S, Moudra A, Vancurova M, Polackova H, Stopka T, Jonasova A, Bokorova R, Fuchs O, Stritesky J, Salovska B, Bartek J, Hodny Z. Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes. Molecular Oncology 2020, 14: 2403-2419. PMID: 32696549, PMCID: PMC7530796, DOI: 10.1002/1878-0261.12768.Peer-Reviewed Original ResearchMeSH KeywordsAntigens, DifferentiationAzacitidineBiomarkersBone MarrowCell CompartmentationCell Line, TumorChemokine CCL2Gene Expression Regulation, NeoplasticHEK293 CellsHumansInterferon-gammaLeukocytes, MononuclearLymphocyte CountMyelodysplastic SyndromesMyeloid CellsNeoplasm ProteinsPrognosisProto-Oncogene MasRNA, MessengerConceptsMyelodysplastic syndromeBone marrowMDS patientsPoor prognosisDisease progressionCandidate biomarkersHigh-risk myelodysplastic syndromeMyeloid-derived suppressor cellsAberrant cytokine levelsAdvanced disease stateMyeloid cell subpopulationsBlast percentageChemokine levelsCytokine levelsLymphocyte countSuppressor cellsPatient groupPeripheral bloodBM plasmaPreleukemic disordersImmune responseProinflammatory signalingMalignant cloneTherapy resistanceLeukemic cells